At Front Line Medical Technologies, our view of REBOA has always been straightforward: when a patient is dying from non-compressible hemorrhage, the technology should help the clinical team gain rapid control with as little additional burden as possible. That means small arterial access, a simple device, thoughtful aortic zone selection, disciplined occlusion time, and an immediate path toward definitive hemorrhage control. Those principles shaped the COBRA-OS® from the beginning, and they continue to shape how we think about REBOA today.
Start by lowering the barrier to access
The original idea behind the COBRA-OS® was not to make REBOA more complicated. It was to remove some of the barriers that had limited its use. Arterial access is one of the most important of those barriers, so we focused on reducing the profile to 4 French. A smaller access platform cannot eliminate every vascular complication, but reducing sheath size is an intuitive and evidence-supported way to reduce access-related burden while simplifying the procedure.
The goal was broader than sheath size alone. We wanted an aortic occlusion system that could be placed quickly, that did not require routine upsizing to a larger sheath, and that could be economical enough to make hemorrhage control more accessible. Severe bleeding is not confined to major trauma centers. A technology intended for hemorrhage control should be practical in the places where bleeding patients actually present, including systems with fewer resources. For us, lowering the barriers to REBOA has always meant thinking about access, complexity, training, and cost together.
Complete occlusion still has an important role
When a patient is rapidly exsanguinating below the level of the balloon, there are moments when the immediate objective is complete hemorrhage control. Complete aortic occlusion can provide that control while supporting central perfusion to the heart and brain. We remain proud that the COBRA-OS® can achieve complete aortic occlusion through a 4 Fr platform because we believe clinicians should retain that capability when the physiology demands it.
The concern with complete occlusion is not theoretical. Distal ischemia accumulates during aortic occlusion, and reperfusion after prolonged ischemia can be harmful. Those realities should shape how complete REBOA is used, but they do not make complete occlusion intrinsically obsolete. They make timing, location, and the transition to definitive hemorrhage control critically important.
A useful way to think about the physiology is that REBOA is the drug, while the zone, degree, and duration of occlusion are the dose. In profound hemorrhage, the appropriate initial dose may need to be decisive. The safety strategy is then to limit exposure: use the occlusion that is required, in the lowest appropriate zone, for the shortest time necessary, while the team moves rapidly toward surgical or endovascular control of the bleeding source.
Time is the variable we should obsess over
Complete REBOA should not become the treatment itself. It is a bridge to the treatment. Once the balloon is inflated, the clock matters. The value of aortic occlusion is greatest when it creates the physiologic space needed to reach an operating room, obtain surgical control, perform embolization, or complete another definitive intervention. The longer complete occlusion substitutes for definitive care, the more its physiologic cost increases.
This is also why Zone 3 deserves generous consideration whenever the bleeding pattern allows it. If effective hemorrhage control can be achieved with infrarenal rather than thoracic aortic occlusion, visceral perfusion can be preserved and the ischemic territory reduced. Zone selection should therefore be a deliberate part of the resuscitation strategy rather than an afterthought. In our view, better REBOA is not simply about whether the balloon is up or down; it is about where it is placed, when it is inflated, how long it remains inflated, and what the team is doing during every minute of occlusion.
The lesson from REBOA should be better use, not more complicated use
REBOA became polarizing in part because early clinical experience occurred while devices, access techniques, training, patient selection, and treatment pathways were all evolving. Larger-bore arterial access, variable protocols, prolonged occlusion, and delays to definitive hemorrhage control can all influence outcomes. It is difficult to judge any resuscitative technology without considering the system in which it is being used.
That history reinforces our belief that the next generation of REBOA should become more deliberate rather than more complicated. Low-profile access should be the default where feasible. Teams should know their intended occlusion zone before the balloon is inflated. Complete occlusion time should be actively minimized, not passively observed. Definitive hemorrhage control should already be moving forward. The device should support that workflow rather than become the focus of it.
Lowering the barriers to hemorrhage control
Our ambition for the COBRA-OS® has always been larger than building a smaller balloon catheter. We want to lower the barriers to effective hemorrhage control. That means a low-profile platform, a simple workflow, an economical approach, thoughtful use of Zone 3, disciplined occlusion times, and a constant focus on getting the patient to definitive care.
We believe REBOA is at its best when it is treated as a powerful resuscitative tool rather than a destination. Used thoughtfully, it can create something extraordinarily valuable in catastrophic hemorrhage: time. Our responsibility is to make that time as safe, useful, and accessible as possible.
